Medicare prescription drug cost, prescriptions and prescribers, 2024
Medicare cost, 2024
$84.9M
+47.3% from 2023
Prescriptions
4,801
$17,681.24 per claim
Patients
656
742 prescribers
Total spending, 2024
$84.9M
$129,401.91 per patient
Medicare prescription drug plans paid $84.9M for Retevmo in 2024, for 4,801 prescriptions and refills to 656 patients (up 47.3% from 2023). The average cost per claim was $17,681.24.
California had the highest Medicare cost for Retevmo in 2024: $17.4M for 995 claims, followed by New York ($5.7M).
Ashray Maniar, hematology-oncology in Portland, OR, had the highest Medicare cost for Retevmo in 2024: 48 claims costing $932K.
Retevmo is made by Eli Lilly and Company (LLY), listed in the Medicare spending data as Eli Lilly & Co..
All plans and makers
Where the prescribers practice, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Ashray Maniar Portland, OR | Hematology-Oncology | 48 | Under 11 | $932K |
| Douglas W Ball Baltimore, MD | Endocrinology | 55 | Under 11 | $779K |
| Victoria M Villaflor |
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 425 | 2,588 | 376 | $44.2M |
| 2023 | 531 | 3,253 | 478 | $57.6M |
| 2024 | 742 | 4,801 | 656 | $84.9M |
Amount reimbursed by state Medicaid programs, all states
More drugs: top Medicare drugs by cost and the Prescriptions tab.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
| Medical Oncology |
| 28 |
| Under 11 |
| $627K |
| Anh Pham Duarte, CA | Hematology-Oncology | 31 | Under 11 | $626K |
| Sai-Hong I Ou Orange, CA | Internal Medicine | 27 | Under 11 | $620K |
| Michael M Buljan San Francisco, CA | Nurse Practitioner | 26 | Under 11 | $540K |
| Gregory A Durm Indianapolis, IN | Internal Medicine | 34 | Under 11 | $524K |
| Douglas E Laux Iowa City, IA | Medical Oncology | 19 | Under 11 | $517K |
| Suresh S Ramalingam Atlanta, GA | Medical Oncology | 26 | Under 11 | $508K |
| Eric J Sherman Philadelphia, PA | Medical Oncology | 32 | Under 11 | $504K |
| Hatim Husain San Diego, CA | Hematology-Oncology | 23 | Under 11 | $496K |
| Kenneth B Ain Lexington, KY | Endocrinology | 22 | Under 11 | $489K |
| Mabel M Ryder Rochester, MN | Endocrinology | 32 | Under 11 | $485K |
| Shirish M Gadgeel Detroit, MI | Medical Oncology | 21 | Under 11 | $429K |
| George G Miranda Mission Viejo, CA | Hematology-Oncology | 20 | Under 11 | $421K |
| Karen E Quinn Boston, MA | Nurse Practitioner | 22 | Under 11 | $416K |
| Therese M Hanley Boston, MA | Nurse Practitioner | 17 | Under 11 | $392K |
| Jonathan W Riess Sacramento, CA | Hematology-Oncology | 27 | Under 11 | $389K |
| Zili He X Flushing, NY | Hematology-Oncology | 15 | Under 11 | $369K |
| Tejas Patil Aurora, CO | Medical Oncology | 19 | Under 11 | $355K |
| Alexander Edward D Drilon New York, NY | Medical Oncology | 21 | Under 11 | $355K |
| Bo Zhao Williamsburg, VA | Hematology-Oncology | 15 | Under 11 | $346K |
| Angela D Larsh Seattle, WA | Nurse Practitioner | 22 | Under 11 | $345K |
| Sasan Fazeli Duarte, CA | Endocrinology | 21 | Under 11 | $338K |
| Stephanie Ossowski San Diego, CA | Internal Medicine | 21 | Under 11 | $329K |
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Eli Lilly & Co. LLY | 4,801 | $84.9M |